- Home
- / Orchard Therapeutics
Orchard TherapeuticsOrchard Therapeutics
Revenue
$1.7 M
FY, 2021
Market Capitalization
$56.8 M
2022-09-20
Orchard Therapeutics Summary
Company summary
- Overview
- Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
- Type
- Public
- Founded
- 2015
- HQ
- London, GB | view all locations
- Website
- https://www.orchard-tx.com/
- Cybersecurity rating
- ESG rating
- out of 100 | View all ESG data
Key people
John Cerio, Chief Human Resource Officer
Anne Dupraz-Poiseau, Chief Development Officer
John Ilett, Chief of Staff, Chief Legal Officer, Company Secretary
LocationsView all
5 locations detected
London, England HQ
United Kingdom
108 Cannon St
Boston, MA
United States
101 Seaport Blvd 7th floor
Boston, MA
United States
2 Seaport Ln 8th floor
Foster City, CA
United States
1118 Chess Dr
Menlo Park, CA
United States
1360 O'Brien Dr
Orchard Therapeutics Financials
Summary financials
- Revenue (Q2, 2022)
- $4.4M
- Gross profit (Q2, 2022)
- $3.2M
- Net income (Q2, 2022)
- ($50.9M)
- Cash (Q2, 2022)
- $53.5M
- EBIT (Q2, 2022)
- ($44.7M)
- Enterprise value
- $36.4M
